RBC Capital Maintains Outperform on Amgen, Raises Price Target to $470

By Benzinga Newsdesk

RBC Capital analyst Luca Issi maintains Amgen (NASDAQ:AMGN) with a Outperform and raises the price target from $430 to $470.

Share this article

Keep reading.

TUTORIALS

RBC Capital Maintains Outperform on Amgen, Raises Price Target to $470

TUTORIALS

8 Of 11 Sectors Rise Wednesday As Growth Leads

TUTORIALS

Intel Stock Implodes, Sheds $434 Billion in 4 Months

Trade what
you just read.

Apply the analysis on a live or demo account, same execution, no risk on demo.

Your seat at the market is ready.

Open your account in minutes, transparent pricing, fast withdrawals and support that answers.

Try a free demo

CFDs are complex instruments. 74% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

RBC Capital Maintains Outperform on Amgen, Raises Price Target to $470

Trade whatyou just read.

Your seat at the market is ready.

Trade what
you just read.